The mechanism of astragaloside IV promoting sciatic nerve regeneration

Xiaohong Zhang¹, Jiajun Chen²

¹ School of Pharmaceutical Sciences, Jilin University, Changchun 130021, Jilin Province, China
² Department of Neurology, China-Japan Union Hospital, Jilin University, Changchun 130033, Jilin Province, China

Research Highlights
(1) Astragaloside IV, the main component of the traditional Chinese medicine astragalus membranaceus, has been shown to exert neuroprotective effects, but studies regarding this compound are limited.
(2) This study assumed that astragaloside IV promoted the repair of sciatic nerve injury, and observed whether its mechanism of action was influenced by growth-associated protein-43 expression.
(3) Astragaloside IV accelerated nerve myelin sheath growth in mice with sciatic nerve injury, increased the diameter and number of myelinated nerve fibers, and elevated and accelerated peripheral nerve regeneration and functional reconstruction by upregulating growth-associated protein-43 expression.

Abstract
3-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosyl-cycloastragenol (astragaloside IV), the main active component of the traditional Chinese medicine astragalus membranaceus, has been shown to be neuroprotective. This study investigated whether astragaloside IV could promote the repair of injured sciatic nerve. Denervated sciatic nerve of mice was subjected to anastomosis. The mice were intraperitoneally injected with 10, 5, 2.5 mg/kg astragaloside IV per day for 8 consecutive days. Western blot assay and real-time PCR results demonstrated that growth-associated protein-43 expression was upregulated in mouse spinal cord segments L₄₋₆ after intervention with 10, 5, 2.5 mg/kg astragaloside IV per day in a dose-dependent manner. Luxol fast blue staining and electrophysiological detection suggested that astragaloside IV elevated the number and diameter of myelinated nerve fibers, and simultaneously increased motor nerve conduction velocity and action potential amplitude in the sciatic nerve of mice. These results indicated that astragaloside IV contributed to sciatic nerve regeneration and functional recovery in mice. The mechanism underlying this effect may be associated with the upregulation of growth-associated protein-43 expression.

Key Words
neural regeneration; traditional Chinese medicine; peripheral nerve injury; astragaloside IV; growth-associated protein-43; sciatic nerve; nerve myelin sheath; myelinated nerve; axons; neuroregeneration
INTRODUCTION

The outcomes of conventional surgical and conservative medical treatment for peripheral nerve injury have been disappointing\(^{1-2}\). Recent studies confirmed that natural medicine can stimulate nerve growth factor expression after nerve injury, and promote peripheral nerve regeneration and functional recovery\(^{2,9}\). These results indicated that natural medicine could be a new method for promoting the repair of peripheral nerve injury.

3-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosyl-cycloastragenol, astragaloside IV, is a major active component of the traditional Chinese medicine astragalus membranaceus, and its structure is shown in Figure 1.

![Chemical structure of astragaloside IV](image)

Astragaloside IV can inhibit inflammation, oxidation, and apoptosis, and exerts immunoregulatory effects. This compound also protects the heart, intestines and stomach\(^{10-11}\). In the central nervous system, astragaloside IV has contributed to nerve repair after cerebral ischemia/reperfusion injury\(^{8}\), accelerated axon growth in mouse hippocampi, prevented neuronal atrophy and memory loss\(^{12}\), and suppressed spontaneous synaptic conduction and Ca\(^{2+}\) oscillation in hippocampal neurons\(^{10}\). Astragaloside IV also protected primary cultured nigral cells against 6-hydroxydopamine-induced injury\(^{13}\). Additionally, astragaloside IV combined with ginsenoside prevented oxidative damage of adult PC 12 cells and protected mitochondrial membrane potential\(^{14}\). In the peripheral nervous system, astragaloside IV also can protect and promote peripheral nerve regeneration\(^{1-2}\).

Neural growth-associated protein 43 guides neuronal growth and branching during neural development and regeneration, possibly inducing changes in the presynaptic membrane and neurotransmitter release, thus promoting long-term potentiation, spatial memory and learning\(^{15-17}\).

Previous studies suggested that growth-associated protein 43 expression gradually increased in the corpus striatum and ipsilateral ischemic cortex after cerebral ischemia/reperfusion. This increase in the ischemic hemisphere occurred to different extents\(^{16-27}\).

This study supposed that astragaloside IV contributed to the repair of sciatic nerve injury, and its mechanisms were associated with the upregulation of growth-associated protein 43 that is involved in axonal regeneration. This study observed the effects of astragaloside IV on peripheral nerve regeneration and functional recovery in a mouse model of sciatic nerve injury, and also determined the expression of growth-associated protein 43 during peripheral nerve regeneration. The mechanism of action of astragaloside IV on peripheral nerve regeneration and functional recovery was also investigated.

RESULTS

Quantitative analysis of experimental animals

A total of 169 BALB/c mice were used in the study, with nine dying during anesthesia. The remaining 160 mice were used to establish a model of sciatic nerve injury by denervating the left sciatic nerve. After model induction, mice were equally and randomly assigned to model, high-, moderate-, or low-dose astragaloside IV groups, and were intraperitoneally injected with saline 1 mL, or 10, 5, or 2.5 mg/kg astragaloside IV per day, respectively, for 1, 2, 4, and 8 consecutive weeks. Ten mice from each group were used at each time point. One hundred and sixty mice were included in the final analysis.
Astragaloside IV accelerated the recovery of sciatic nerve function in mice
Electrophysiology results suggested that at 1, 2, 4, and 8 weeks after sciatic nerve injury, sciatic nerve conduction amplitude and velocity were gradually increased in each group. The recovery of sciatic nerve was significantly better in the high- and moderate-dose astragaloside IV groups than that in the low-dose astragaloside IV and model groups (P < 0.05; Tables 1, 2).

### Table 1 Effects of astragaloside IV on sciatic nerve conduction amplitude (mV) in mice with sciatic nerve injury

| Group          | Post-injury (week) |
|----------------|--------------------|
| Astragaloside IV |                    |
| High-dose      | 2.08±0.21ab        |
| Moderate-dose  | 2.07±0.18ab        |
| Low-dose       | 1.32±0.13          |
| Model          | 1.19±0.06          |

*P < 0.05, vs. model group; *P < 0.05, vs. low-dose astragaloside IV group. Data are expressed as mean ± SD. Ten mice at each time point (one-way analysis of variance and least significant difference t-test). High-, moderate- and low-dose astragaloside IV groups were intraperitoneally injected with 10, 5 and 2.5 mg/kg per day, respectively.

Astragaloside IV upregulated growth-associated protein 43 mRNA expression in spinal cord segments L₄-₅ of mice with sciatic nerve injury
Real-time PCR revealed that growth-associated protein 43 mRNA contents gradually increased in corresponding spinal cord segments in the low-dose astragaloside IV and model groups. This mRNA expression peaked at 4 weeks after sciatic nerve injury, and decreased at 8 weeks. Compared with the low-dose astragaloside IV and model groups, growth-associated protein 43 mRNA expression significantly increased in the high-dose and moderate-dose astragaloside IV groups (P < 0.05).

### Table 2 Effects of astragaloside IV on motor nerve conduction velocity (m/s) in mice with sciatic nerve injury

| Group          | Post-injury (week) |
|----------------|--------------------|
| Astragaloside IV |                    |
| High-dose      | 19.96±0.32ab       |
| Moderate-dose  | 18.73±0.31ab       |
| Low-dose       | 12.88±0.19         |
| Model          | 10.41±0.18         |

*P < 0.05, vs. model group; *P < 0.05, vs. low-dose astragaloside IV group. Data are expressed as mean ± SD. Ten mice at each time point (one-way analysis of variance and least significant difference t-test). High-, moderate- and low-dose astragaloside IV groups were intraperitoneally injected with 10, 5 and 2.5 mg/kg per day, respectively.

### Figure 2 Effects of astragaloside IV on growth-associated protein 43 (GAP-43) mRNA expression in spinal cord segments L₄-₅ in mice with sciatic nerve injury.
High-, moderate- and low-dose astragaloside IV groups were intraperitoneally injected with 10, 5 and 2.5 mg/kg per day, respectively. The measurement data were expressed as the CI ratio of growth-associated protein 43/glyceraldehyde-phosphate dehydrogenase (GAPDH). Data are expressed as mean ± SD. Ten mice from each group were used at each time point. *P < 0.05, vs. model group; *P < 0.05, vs. low-dose astragaloside IV group; *P < 0.05, vs. moderate-dose astragaloside IV group. One-way analysis of variance and least significant difference t-test were used.

Astragaloside IV upregulated growth-associated protein 43 protein expression in spinal cord segments L₄-₅ of mice with sciatic nerve injury
Western blot assay results revealed that growth-associated protein 43 protein expression reached a peak in each group at 1 week after sciatic nerve injury, and then gradually decreased. Compared with the model group, growth-associated protein 43 protein expression was significantly higher in the high-dose and moderate-dose astragaloside IV groups at various time points (P < 0.05). Moreover, growth-associated protein 43 protein expression was also significantly upregulated in the low-dose astragaloside IV group at 1, 2 and 4 weeks after injury (P < 0.05). No significant difference in growth-associated protein 43 protein expression was detectable between the low-dose astragaloside IV group and model group at 8 weeks. Growth-associated protein 43 protein expression was significantly greater in the high-dose and moderate-dose astragaloside IV groups than that in the low-dose astragaloside IV group at various time points after injury (P < 0.05), and the upregula-
tion was most significant in the high-dose astragaloside IV group (Figure 3, Table 3).

Table 3  Effects of astragaloside IV on growth-associated protein 43 protein expressions in spinal cord segments L₄-₆ in mice at various time points after sciatic nerve injury

| Group              | Post-injury (week) |
|--------------------|--------------------|
|                    | 1  | 2  | 4  | 8  |
| Astragaloside IV   |    |    |    |    |
| High-dose          | 0.59±0.02ab | 0.46±0.03ab | 0.27±0.03ab | 0.21±0.04ab |
| Moderate-dose      | 0.51±0.02ab | 0.43±0.02ab | 0.37±0.01ab | 0.21±0.02ab |
| Low-dose           | 0.41±0.03ab | 0.34±0.04ab | 0.32±0.03ab | 0.12±0.02ab |
| Model              | 0.27±0.03  | 0.20±0.02  | 0.19±0.02  | 0.12±0.02  |

Gray value ratio of growth-associated protein 43/reduced glyceraldehyde-phosphate dehydrogenase (GAPDH) was expressed as mean ± SD. High grayscale ratio indicates a high level of growth-associated protein 43 protein expression. Ten mice were designated for each time point in each group. *P < 0.05, vs. model group; **P < 0.05, vs. low-dose astragaloside IV group (n = 10). One-way analysis of variance and least significant difference t-test were used. High-, moderate- and low-dose astragaloside IV groups were intraperitoneally injected with 10, 5 and 2.5 mg/kg per day, respectively.

Astragaloside IV promoted the remyelination of sciatic nerve in model mice

Luxol fast blue staining revealed the structure of the myelin sheath around mouse sciatic nerves. Function of the sciatic nerve was mostly recovered at 8 weeks after sciatic nerve injury; therefore, sciatic nerve samples were stained with Luxol fast blue at 8 weeks after injury to observe the effects of astragaloside IV on the sciatic nerve myelin sheath. The sciatic nerve myelin sheath was found to be regular and uniform, with an obvious outline in the high-dose and moderate-dose astragaloside IV groups (Figure 4A, B). By contrast, the sciatic nerve myelin sheath was irregular, with a clear outline in the low-dose astragaloside IV group. Furthermore, fibrous connective tissue hyperplasia was visible among nerve bundles (Figure 4C). The sciatic nerve myelin sheath was irregular, and fibrous connective tissue hyperplasia was also apparent in the model group (Figure 4D). Compared with the model group, sciatic nerve myelin sheath regeneration was clearly promoted in the high-dose and moderate-dose astragaloside IV groups, especially in the high-dose astragaloside IV group.
Table 4  Effects of astragaloside IV on the number and diameter of myelinated nerve fibers in mice at 8 weeks after sciatic nerve injury

| Group          | The number of myelinated nerve fibers (n/mm²) | Diameter of myelinated nerve fiber (μm) |
|----------------|---------------------------------------------|----------------------------------------|
| Astragaloside IV |                                             |                                        |
| High-dose      | 75±3ᵃᵇ                                            | 2.47±0.31ᵃᵇ                           |
| Moderate-dose  | 71±1ᵃᵇ                                            | 2.31±0.16ᵃᵇ                           |
| Low-dose       | 56±4ᵃᵇ                                            | 1.99±0.32ᵃᵇ                           |
| Model          | 50±2                                            | 1.57±0.26                              |

Data are expressed as mean ± SD (n = 10). ⁿ<sup>P</sup> < 0.05, vs. model group; ⁿ<sup>P</sup> < 0.05, vs. low-dose astragaloside IV group. One-way analysis of variance and least significant difference t-test were used. High-, moderate- and low-dose astragaloside IV groups were intraperitoneally injected with 10, 5 and 2.5 mg/kg per day, respectively.

**DISCUSSION**

Astragaloside IV promotes neural regeneration or prevents neural injury through various mechanisms<sup>[1, 9-14]</sup>. Growth-associated protein 43 is highly expressed in individual neurons during development and adult cerebral hippocampal neurons<sup>[29-31]</sup>. Growth-associated protein 43 is a sensitive specific molecular marker present during nerve injury and repair, and plays an important role in nerve growth, development and regeneration<sup>[32-35]</sup>. During axon regeneration in the central nervous system, growth-associated protein 43 expression is significantly upregulated, which clearly promotes neural regeneration and repair<sup>[36-41]</sup>. Thus, this study established a mouse model of sciatic nerve injury, and observed the effects of astragaloside IV on peripheral nerve regeneration, functional recovery, and growth-associated protein 43 expression during peripheral nerve regeneration.

In this study, Luxol fast blue staining was used to determine the changes in sciatic nerve myelin sheath structure, and results revealed that high-dose and moderate-dose astragaloside IV accelerated the growth of myelin sheath surrounding injured sciatic nerve, increased the number and diameter of myelinated nerve fibers, contributed to neural regeneration and structural reconstruction, and elevated the quality of regenerating nerve. Electrophysiological detection suggested that regenerating sciatic nerve had good structure at 8 weeks, showing good motor nerve conduction velocity and action potential amplitude. Results of electrophysiological detection completely coincided with the results of Luxol fast blue staining.

Growth-associated protein 43 expression was lower in spinal cord segments L₄-₆ from normal Balb/c mice<sup>[42-47]</sup>, active in growing neuronal axons, and strongly associated with neuronal axon growth<sup>[54, 48-50]</sup>. In the present study, western blot assay and real-time PCR results demonstrated that growth-associated protein 43 expression was activated and highly expressed in corresponding spinal cord segments of mice with sciatic nerve injury. Growth-associated protein 43 expression was significantly greater in the high-dose and moderate-dose astragaloside IV groups than in the low-dose astragaloside IV group and model group within 4 weeks. These results suggested that high-dose and moderate-dose astragaloside IV apparently upregulated growth-associated protein 43 expression in regenerating nerve tissues. Moreover, this promoting effect could last at least 4 weeks. At 8 weeks, growth-associated protein 43 expression was identical between high- and moderate-dose astragaloside IV groups and the model group. However, astragaloside IV promoted the upregulation of growth-associated protein 43 expression for up to 4 weeks, so the structure and function of the sciatic nerve in the astragaloside IV groups were better than those in the model group. Gerin et al<sup>[37]</sup> confirmed that endogenous repair genes including growth-associated protein 43 are persistently expressed for 12 weeks following spinal cord injury. Therefore, this study presumed that growth-associated protein 43 was probably persistently expressed in the 4 weeks following insult in each group<sup>[46]</sup>, which contributed to the regeneration and repair of sciatic nerve, but was further stimulated by the treatment with astragaloside IV.

Appropriate expression of growth-associated protein 43 promotes neural recovery and regeneration, but excessive expression can contribute to inflammatory reaction and scar formation, and suppress myelin sheath growth<sup>[2, 51-57]</sup>. In this study, upregulation of growth-associated protein 43 expression promoted peripheral nerve regeneration, indicating that high-dose and moderate-dose astragaloside IV was in an appropriate range, all of which contributed to growth-associated protein 43 expression and exerted an accelerated regulatory effect on neural regeneration. In the high-dose and moderate-dose astragaloside IV groups, growth-associated protein 43 mRNA maintained a stable high expression at 1, 2 and 4 weeks, and showed a decreased expression at 8 weeks. Growth-associated protein 43 protein expression peaked at 1 week, and then gradually diminished. The expression of mRNA and protein showed a certain asynchrony, indicating that there was endogenous translational control or
post-translational control. High levels of growth-associated protein 43 protein may have been upregulated to avoid neural injury. The promoting effect of astragaloside IV on neural regeneration possibly has multiple molecular mechanisms. This study also presumed that astragaloside IV had a persistent promoting effect (at least for 4 weeks) on activation of growth-associated protein 43 in the spinal cord segments L₄–₆ after sciatic nerve injury, resulting in a positive regulatory effect on peripheral nerve regeneration and functional recovery.

In summary, astragaloside IV elevated and accelerated peripheral nerve regeneration and functional reconstruction, which is associated with its regulatory effect on growth-associated protein 43 expression.

MATERIALS AND METHODS

Design
A randomized, controlled animal study.

Time and setting
Experiments were performed at the National Key Laboratory, Central Laboratory, China-Japan Union Hospital, Jilin University, China from November 2010 to May 2011.

Materials
Animals
Healthy clean male BALB/c mice, aged 8 weeks old and weighing 20 ± 2 g, were provided by the Experimental Animal Center, School of Basic Medicine, Jilin University, China (license No. SCXK (Ji) 2007-0001). The protocols were conducted in accordance with the Guidance Suggestions for the Care and Use of Laboratory Animals, formulated by Ministry of Science and Technology of China.[58]

Drugs
Astragaloside IV was purchased from the National Institute for Food and Drug Control in China. Astragaloside IV was dissolved using dimethyl sulfoxide to create a stock solution of 10 g/L, and diluted with saline to working concentrations[59].

Methods
Preparation of a mouse model of sciatic nerve injury
BALB/c mice were intraperitoneally anesthetized with 1% sodium thiopental, and fixed in the prone position. Under aseptic conditions, a 2-cm longitudinal incision was made at the posterior thigh of the left hindlimb. The sciatic nerve was exposed at the inferior border of the piriform muscle. The trunk and surrounding tissues of the sciatic nerve were bluntly separated using a glass needle. The sciatic nerve was completely denervated at 0.5 cm below the ischial tuberosity. Ten minutes later, the sciatic nerve was anastomosed using 11/0 sutures under a 12-fold microscope (Surgery Microinstrument Factory, Zhenjiang, Jiangsu Province, China), and muscle and skin were separately sutured closed (Figure 5)[60].

Drug intervention
The dose of astragaloside IV was consistent with the amount of original astragaloside IV administered clinically, and was found to be equivalent to the intraperitoneal dose of 5 mg/kg per day. This amount was considered a moderate dose. 10 mg/kg per day and 2.5 mg/kg per day were considered high and low doses, respectively. Administration was performed immediately after model induction. Mice in the high-, moderate- and low-dose astragaloside IV groups were intraperitoneally injected with 10, 5, 2.5 mg/kg astragaloside IV per day[59] (dissolved in dimethyl sulfoxide, diluted in saline), respectively. Mice in the model group were given 1 mL/d saline. Drug administration was consecutively performed until experiments were complete or samples were collected.

Neuroeletrophysiology for the recovery of sciatic nerve function in mice after astragaloside IV intervention
Bilateral sciatic nerves of mice were investigated using a Medtronic Keypoint electromyograph machine (Medtronic Corporation, Minneapolis, MN, USA) at 1, 2, 4 and 8 weeks after model establishment. Room temperature was maintained at 24°C. Animals were intraperitoneally anesthetized with 1% sodium triopental. After disinfection, the sciatic nerve was exposed in a prone position. Centric needle electrodes were placed in the mouse soleus muscle as a recording electrode (M point). A ground electrode was placed in the mouse tail. Super-strong stimuli (current 10 mA) were given at the level of the
ischial tuberosity proximal to the anastomotic stoma (P point) and the branch of the distal sciatic nerve (D point) using double head stimulating electrodes (the distance between the two electrodes was 2 mm). The distance between the electrodes P-D was measured using a vernier caliper to calculate the difference of action potential latency, which represents the time the nerve impulse to traverse the two points. Motor nerve conduction velocity of sciatic nerve was equal to the distance of P-D/difference of action potential latency (m/s). Simultaneously, motor nerve action potential amplitude of the sciatic nerve (mV) was measured using the vernier caliper.

Sample collection
A total of 10 mice from each group were obtained at 1, 2, 4 and 8 weeks after injury. They were intraperitoneally anesthetized with 1% sodium thiopental. A median incision was made at the posterior spine, and the vertebral canal was opened with bone forceps. Spinal cord segments L4–6, connected to the sciatic nerve, were intact and exposed (Figure 6). Spinal cord segments L4–6 from the injured side were obtained, marked and rapidly immersed in liquid nitrogen for western blot assay and real-time PCR. In addition, sciatic nerve trunk from anastomotic stoma (0.5 cm, including the anastomotic stoma) to the distal end was obtained and fixed in 10% neutral formalin over 72 hours, dehydrated through a graded alcohol series, embedded in paraffin, and sliced into 2-μm-thick sections.

Real-time PCR for growth-associated protein 43 mRNA expression in spinal cord segments L4–6 of mice
Growth-associated protein 43 and reduced glyceraldehyde-phosphate dehydrogenase (GAPDH) primers were designed using Beacon designer 7 software (PREMIER Biosoft, Palo Alto, CA, USA) in accordance with NCBI Genbank (http://www.ncbi.nlm.nih.gov/genbank/). Primers were synthesized by Sangon Biotech (Shanghai) Co., Ltd., Shanghai, China. Primer sequences are listed in Table 5.

| Primer name | Sequence | Product size (bp) |
|-------------|----------|-----------------|
| GAP-43 Upstream | 5’-GCC TAA ACA AGC CTA TGT GC-3’ | 276 |
| Downstream | 5’-TTC GTG TAC AGC GTC TTT CTC C-3’ | |
| Probe | 5’-TGC TGC TGT AGC TGA TGC TGC TGT-3’ | |
| GAPDH Upstream | 5’-AAT GTG TCC GTG GTG GAT CTG-3’ | 462 |
| Downstream | 5’-CAA CCT GTG CCT CAG TGT AGC-3’ | |
| Probe | 5’-CGT GCC GCC TGG AGA AAG CTG CC-3’ | |

GAP-43: Growth-associated protein-43; GAPDH: reduced glyceraldehyde-phosphate dehydrogenase.

Spinal cord segments L4–6 were obtained at various time points. Total RNA was extracted using an extraction kit [Sangon Biotech (Shanghai) Co., Ltd.] using the TRIzol reagent method. First-strand cDNA was synthesized with a reverse transcription kit (M-MLV RTase Kit, Promega, Beijing, China), and cDNA was synthesized further. cDNA served as a template. Real-time PCR was used to amplify growth-associated protein 43 in the spinal cord segments L4–6. A 2 × SYBR real-time quantitative PCR kit was purchased from Roche (Beijing, China). Reaction conditions were as follows: 95°C for 30 seconds, 58°C for 60 seconds, and 72°C for 60 seconds, 40 cycles in total. GAPDH served as an internal reference. Stratagene Mx3000P Real-Time QPCR System (Agilent Technologies, Beijing, China) was used to detect the Ct values of growth-associated protein 43 and internal reference gene (Stratagene MxPro QPCR Software, Agilent Technologies, Beijing, China). Relative mRNA expression of growth-associated protein 43/GAPDH was calculated.

Western blot assay for growth-associated protein 43 protein expression in the spinal cord segments L4–6 of mice
Spinal cord segments L4–6 were obtained at various time points and triturated in a mortar with RIPA lysis buffer. Total protein was extracted with an extraction kit (Beyotime Institute of Biotechnology, Nanjing, Jiangsu Province, China). After adding loading buffer, samples were boiled in water for 15 minutes. After centrifugation, the supernatant was obtained and electrophoresed on 12% sodium dodecyl sulfate-polyacrylamide gel, and electro-transferred onto polyvinylidene fluoride membrane using...
the wet method[9]. The membrane was immersed in rabbit anti-mouse growth-associated protein 43 or GAPDH antibody (1:1000; Roche, Shanghai, China) at 4°C overnight. After four washes with 0.01 mol/L PBS (each for 5 minutes), the membrane was incubated in goat anti-rabbit IgG (1:10000; Roche) at room temperature for 1 hour. After four washes with 0.01 mol/L PBS (each for 5 minutes), the membrane was visualized in accordance with the instructions from the enhanced chemiluminescence kit (Roche). X-ray film was exposed and analyzed using a gel image processing system (UV-EC3 600 Imaging System, UVP LLC, Upland, CA, USA).

Gray values of target blots were analyzed with an image processing system using VisionWorksLS software, and relative gray values (growth-associated protein-43/ GAPDH) were calculated.

**Luxol fast blue staining for the diameter and number of myelinated nerve fibers in mouse sciatic nerve**

Sciatic nerve trunk from the anastomotic stoma (0.5 cm, including the anastomotic stoma) to the distal end was obtained and fixed in 10% neutral formalin for > 72 hours, dehydrated through a graded alcohol series, embedded in paraffin, and sliced into sections of 3.0 µm. After deparaffinization, the samples were immersed in Luxol fast blue staining solution at 60°C for 12 hours, then subsequently immersed in 95% alcohol for 5 minutes, and treated with 0.05% lithium carbonate for 15 seconds. After a wash with 70% alcohol, the samples were washed with distilled water, dehydrated, permeabilized, mounted, observed and photographed with a light microscope (Eclipse TE-2000-U, Nikon, equipped with an attached digital camera SXM1200F, Tokyo, Japan). The diameter and number of myelinated nerve fibers were determined using an image scanner (Olympus, Tokyo, Japan).

**Statistical analysis**

Measurement data were expressed as mean ± SD and analyzed using SPSS 17.0 software (SPSS, Chicago, IL, USA). Mean difference among multiple groups was compared using one-way analysis of variance. Paired comparison of intergroup mean difference was performed using least significant difference comparison. A value of P < 0.05 was considered statistically significant.

**REFERENCES**

[1] Yu J, Zhang Y, Sun S, et al. Inhibitory effects of astragaloside IV on diabetic peripheral neuropathy in rats. Can J Physiol Pharmacol. 2006;84(6):579-587.

[2] Cheng CY, Yao CH, Liu BS, et al. The role of astragaloside in regeneration of the peripheral nerve system. J Biomed Mater Res A. 2006;76(3):463-469.

[3] Qiu D, Zhao G, Aoki Y, et al. Immunosuppressant PG490 (triptolidine) inhibits T-cell interleukin-2 expression at the level of purine-box/nuclear factor of activated T-cells and NF-kappa B transcriptional activation. J Biol Chem. 1999;274(19):13443-13450.

[4] Xue B, Jiao J, Zhang L, et al. Triptolidine upregulates NF synthesis in rat astrocyte cultures. Neurochem Res. 2007;32(7):1113-1119.

[5] Ye M, Xie WD, Lei F, et al. Brazilein, an important immunosuppressive component from Caesalpinia sappan L. Int Immunopharmacol. 2006;6(3):426-432.

[6] Yang EB, Zhao YN, Zhang K, et al. Daphnetin, one of coumarin derivatives, is a protein kinase inhibitor. Biochem Biophys Res Commun. 1999;260(3):682-685.

[7] Tohda C, Tamura T, Matsuyama S, et al. Promotion of axonal maturation and prevention of memory loss in mice by extracts of Astragalus mongholicus. Br J Pharmacol. 2006;149(5):532-541.

[8] Yin YY, Li WP, Gong HL, et al. Protective effect of astragaloside on focal cerebral ischemia/reperfusion injury in rats. Am J Chin Med. 2010;38(3):517-527.

[9] Zhang ZG, Wu L, Wang JL, et al. Activity of Astragaloside IV promotes spontaneous synaptic transmission and synchronizes Ca²⁺ oscillations on hippocampal neurons. Acta Pharmacol Sin. 2008;29(1):57-64.

[10] Zhang C, Wang XH, Zhong MF, et al. Mechanisms underlying vasorelaxant action of astragaloside IV in isolated rat aortic rings. Clin Exp Pharmacol Physiol. 2007;34(5-6):387-392.

[11] Cheng CY, Yao CH, Liu BS, et al. The role of astragaloside in regeneration of the peripheral nerve system. J Biomed Mater Res A. 2006;76(3):463-469.

[12] Huang XP, Liu XD, Deng CQ. Effects of the combination of Astragaloside IV on diabetic peripheral neuropathy in rats. Clin Exp Pharmacol Physiol. 2007;34(5-6):387-392.

[13] Chan WS, Durairajan SS, Lu JH, et al. Neuroprotective effects of Astragaloside IV in 6-hydroxydopamine-treated primary nigral cell culture. Neurochem Int. 2009;55(6):414-422.

[14] Ye M, Xie WD, Lei F, et al. Brazilein, an important immunosuppressive component from Caesalpinia sappan L. Int Immunopharmacol. 2006;6(3):426-432.

[15] Denny JB. Molecular mechanisms, biological actions, and neuropharmacology of the growth-associated protein.
GAP-43. Curr Neuropharmacol. 2006;4(4):293-304.

[17] Korshunova I, Mosevitsky M. Role of the growth-associated protein GAP-43 in NCAM-mediated neurite outgrowth. Adv Exp Med Biol. 2010;663:169-182.

[18] Zheng GY, Shi WQ, Chen XD, et al. Influence of ilexin A on the expression of bFGF, GAP-43 and neurogenesis after cerebral ischemia-reperfusion in rats. Yao Xue Xue Bao. 2011;46(9):1065-1071.

[19] Hou DR, Shaddie S, Deng JF, et al. Effect of willied movement therapy on the expression of neurotrophin 3 and growth-associated protein 43 in rats with cerebral ischemia reperfusion. Nan Fang Yi Ke Da Xue Xue Bao. 2011;31(8):1401-1404.

[20] Zhou ZW, Yang J, Yang QD, et al. Effects of tetrahydroxystilbene glucoside on nerve growth factor and growth associated protein in rats after cerebral ischemia-reperfusion. Zhong Yao Cai. 2010;33(7):1120-1124.

[21] Niu L, Zhou J, Huang Y, et al. db-Cyclic adenosine monophosphate promotes axon regeneration and motor function recovery in cerebral ischemia-reperfusion rats. Neurrol India. 2010;58(2):195-200.

[22] Yang J, Zhou Z, Yang Q, et al. Neuroprotective mechanism of tetrahydroxystilbene glucoside on rats after cerebral ischemia-reperfusion. Zhong Nan Da Xue Bao Yi Xue Ban. 2010;35(4):321-328.

[23] Dijk F, Bergen AA, Kamphuis W. GAP-43 expression is upregulated in retinal ganglion cells after ischemia-reperfusion-induced damage. Exp Eye Res. 2007; 84(5):858-867.

[24] Ju WK, Gwon JS, Park SJ, et al. Growth-associated protein 43 is up-regulated in the ganglion cells of the ischemic rat retina. Neuroreport. 2002;13(6):861-865.

[25] Li Y, Jiang N, Powers C, et al. Neuronal damage and plasticity identified by microtubule-associated protein 2, growth-associated protein 43, and cyclin D1 immunoreactivity after focal cerebral ischemia in rats. Stroke. 1998; 29(9):1972-1980.

[26] Li Y, Bickel KD, Im MJ, et al. Effects of deferoxamine on ischemia/reperfusion injury after peripheral nerve compression. Ann Plast Surg. 1996;36(4):365-369.

[27] Tagaya M, Matsuyama T, Nakamura H, et al. Increased F1/GAP-43 mRNA accumulation in gerbil hippocampus after brain ischemia. J Cereb Blood Flow Metab. 1995; 15(6):1132-1136.

[28] Buizza L, Prandelli C, Bonini SA, et al. Conformational altered p53 affects neuronal function: relevance for the response to toxic insult and growth-associated protein 43 expression. Cell Death Dis. 2013;4:e484.

[29] Zhang W, Li Z. The effects of target skeletal muscle cells on dorsal root ganglion neuronal outgrowth and migration in vitro. PLoS One. 2013;8(1):e52849.

[30] Zhang H, Fan S. Expression and significance of growth-associated protein 43 in a rat model of intervertebral disc inflammation. Zhongguo Xiu Fu Chong Jian Wai Ke Za Zhi. 2012;26(12):1435-1441.

[31] Tułodziecka K, Czeredys M, Nałęcz KA. Palmitoylcarnitine affects localization of growth associated protein GAP-43 in plasma membrane subdomains and its interaction with Go(o) in neuroblastoma NB-2a cells. Neurochem Res. 2013;38(3):519-529.

[32] Wu F, Miao X, Chen J, et al. Down-regulation of GAP-43 by inhibition of caspases-3 in a rat model of neuropathic pain. Int J Clin Exp Pathol. 2012;5(9):948-955.

[33] Shen Y, Meiri K. GAP-43 dependency defines distinct effects of netrin-1 on cortical and spinal neurite outgrowth and directional guidance. Int J Dev Neurosci. 2013;31(1):11-20.

[34] Morita S, Miyata S. Synaptic localization of growth-associated protein 43 in cultured hippocampal neurons during synaptogenesis. Cell Biochem Funct. 2012.

[35] Grynspan D, Giassi AC, Cadonic R, et al. Growth-associated protein-43 (GAP-43) expression in ganglionic and aganglionic colon. Pediatr Dev Pathol. 2012.

[36] Zaccaria KJ, McCasland JS. Emergence of layer IV barrel cytoarchitecture is delayed in somatosensory cortex of GAP-43 deficient mice following delayed development of dendritic asymmetry. Somatosens Mot Res. 2012;29(3):77-88.

[37] Gerin CG, Madueke IC, Perkins T, et al. Combination strategies for repair, plasticity, and regeneration using regulation of gene expression during the chronic phase after spinal cord injury. Synapse. 2011;65(12):1255-1281.

[38] Korshunova I, Mosevitsky M. Role of the growth-associated protein GAP-43 in NCAM-mediated neurite outgrowth. Adv Exp Med Biol. 2010;663:169-182.

[39] Manassero G, Repetto IE, Cobianchi S, et al. Role of JNK isoforms in the development of neuropathic pain following sciatic nerve transection in the mouse. Mol Pain. 2012;8:39.

[40] Zhang Z, Zhang H, Du B, et al. Neonatal handling and environmental enrichment increase the expression of GAP-43 in the hippocampus and promote cognitive abilities in prenatally stressed rat offspring. Neurosci Lett. 2012;522(1):1-5.

[41] Xing YH, Leng YF, Wang SX, et al. Clonidine and dexametomidine's effect on the altered expressions of growth associated protein-43 mRNA in rat dorsal root ganglion during the development of chronic neuropathic pain. Zhonghua Yi Xue Za Zhi. 2012;92(7):444-447.

[42] Pascale A, Gusev PA, Amadio M, et al. Increase of the RNA-binding protein HuD and posttranscriptional up-regulation of the GAP-43 gene during spatial memory. Proc Natl Acad Sci U S A. 2004;101(5):1217-1222.

[43] McIvain VA, Robertson DR, Maimone MM, et al. Abnormal thalamocortical pathfinding and terminal arbors lead to enlarged barrels in neonatal GAP-43 heterozygous mice. J Comp Neurol. 2003;462(2):252-264.

[44] Anderson KD, Sengupta J, Morin M, et al. Overexpression of HuD accelerates neurite outgrowth and increases

2264

Zhang XH, et al. / Neural Regeneration Research. 2013;8(24):2256-2265.
GAP-43 mRNA expression in cortical neurons and retinoic acid-induced embryonic stem cells in vitro. Exp Neurol. 2001;168(2):250-258.

[45] Mendonça HR, Araújo SE, Gomes AL, et al. Expression of GAP-43 during development and after monocular enucleation in the rat superior colliculus. Neurosci Lett. 2010; 477(1):23-27.

[46] Tolner EA, Vliet EA, Holtmaat AJ, et al. GAP-43 mRNA and protein expression in the hippocampal and parahippocampal region during the course of epileptogenesis in rats. Eur Neurosci. 2003;17(11):2369-2380.

[47] Mason MR, Lieberman AR, Anderson PN. Corticospinal neurons up-regulate a range of growth-associated genes following intracortical, but not spinal, axotomy. Eur Neurosci. 2003;18(4):789-802.

[48] Benowitz L, Routtenberg A. GAP-43: an intrinsic determinant of neuronal development and plasticity. Trends Neurosci. 1997;20(2):84-91.

[49] Sjögren M, Minthon L, Davidsson P, et al. CSF levels of tau, β-amyloid(1–42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J Neurosci. 2000;17(5):563-579.

[50] Eastwood SL, Harrison PJ. Synaptic pathology in the anterior cingulate cortex in schizophrenia and mood disorders. A review and a Western blot study of synaptophysin, GAP-43 and the complexins. Brain Res Bull. 2001;55(5):569-578.

[51] Dubroff JG, Stevens RT, Hitt J, et al. Anomalous functional organization of barrel cortex in GAP-43 deficient mice. NeuroImage. 2006;29(4):1040-1048.

[52] Donovan SL, Mamounas LA, Andrews AM, et al. GAP-43 is critical for normal development of the serotonergic innervation in forebrain. J Neurosci. 2002;22(9):3543-3552.

[53] Biewenga JE, Schrama LH, Gispen WH. Presynaptic phosphoprotein B-50/ GAP-43 in neuronal and synaptic plasticity. Acta Biochim Pol. 1996;43(2):327-338.

[54] Aigner L, Arber S, Kapfhammer JP, et al. Overexpression of the neural growth-associated protein GAP-43 induces nerve sprouting in the adult nervous system of transgenic mice. Cell. 1995;83(2):269-278.

[55] Vanselow J, Grabczyk E, Ping J, et al. GAP-43 transgenic mice: dispersed genomic sequences confer a GAP-43-like expression pattern during development and regeneration. J Neurosci. 1994;14(2):499-510.

[56] Shain DH, Haile DT, Verrastro TA, et al. Cloning and embryonic expression of Xenopus laevis GAP-43(XGAP-43). Brain Res. 1995;697(1-2):241-246.

[57] He Q, Dent EW, Meiri KF. Modulation of actin filament behavior by GAP-43 (Neuromodulin) is dependent on the phosphorylation status of serine41, the protein kinase C site. J Neurosci. 1997;17(10):3515-3524.

[58] The Ministry of Science and Technology of the People’s Republic of China. Guidance Suggestions for the Care and Use of Laboratory Animals. 2006-09-30.

[59] Huang JH, Huang XH, Chen ZY, et al. Dose conversion among different animals and healthy volunteers in pharmacological study. Zhong Guo Lin Chuang Yao Li Xue Yu Zhi Liao Xue. 2004;9(9):1069-1072.

[60] Cao J, Li LS, Liu B, et al. Activation of growth-associated protein by intragastric brazilein in motor neuron of spinal cord connected with injured sciatic nerve in mice. Chem Res Chin Univ. 2011;27(2):254-257.

(Reviewed by Apricò K, Haase R, Li DF, Yin WT)
(Edited by Wang J, Qiu Y, Li CH, Song LP, Liu WJ, Zhao M)